<DOC>
	<DOCNO>NCT00039858</DOCNO>
	<brief_summary>The purpose study evaluate safe effective dose Argatroban prophylaxis and/or treatment thrombosis pediatric patient current previous diagnosis heparin-induced thrombocytopenia ( HIT ) thrombosis syndrome ( HITTS ) , opinion investigator require alternative anticoagulation due underlying condition .</brief_summary>
	<brief_title>Evaluation Argatroban Injection Pediatric Patients Requiring Anticoagulant Alternatives Heparin</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Argatroban</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Criteria Inclusion : Males female age birth 16 year , inclusive , enrollment . For neonate , minimum correct gestational age 37 week . Documented HIT define fall platelet count le 100,000/uL &gt; =50 % decrease platelets initiation heparin therapy apparent explanation HIT , Require anticoagulation document history positive HIT test absence current thrombocytopenia ( i.e . patient risk HIT ) , In opinion investigator , require alternative anticoagulation due underlying condition , ATIII deficiency heparin resistance . Signed ( write ) inform consent assent patient ( age appropriate ) patient 's parent guardian . Criteria Exclusion : Any condition , investigator 's opinion , would contraindicate use Argatroban would endanger patient he/she participate trial . Unexplained aPTT &gt; 2 time upper limit normal baseline , absence heparin . International Normalized Ratio ( INR ) &gt; 1.6 baseline absence warfarin . Known clinical site bleed predisposition bleeding ( e.g. , GI bleed , hematuria , hemorrhagic CVA , retroperitoneal hematoma , diabetic retinopathy , hemorrhagic pericardial effusion , hemorrhagic pleural effusion . Patients know clinical site bleeding may enrol investigator deems risk continue thrombosis outweigh potential bleeding risk . Any patient receive investigational medication within 30 day prior first dose study medication schedule receive investigational drug Argatroban course study . Known hypersensitivity Argatroban chemically related compound . Females childbearing potential pregnant ( positive serum betaHCG ) , breast feeding , sexually active take adequate contraceptive precaution ( e.g . IUD oral contraceptive ) . Any patient receiving thrombolytic medication ( e.g . tPA ) . Any neonate correct gestational age &lt; = 44 week bleed head ( Grade I ) determine head ultrasound .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>heparin-induced thrombocytopenia</keyword>
	<keyword>heparin-induced thrombocytopenia thrombosis</keyword>
	<keyword>HIT</keyword>
	<keyword>HITTS</keyword>
	<keyword>anticoagulation</keyword>
</DOC>